The public offering of HAIXI PHARMA was oversubscribed by 3,164 times, listing on Monday

AASTOCKS
2025.10.19 11:35

The originally planned listing of HAIXI PHARMA (02637.HK) on last Friday (17th) announced its IPO results, with the Hong Kong public offering receiving 3,165.1 times subscription, a 1% chance of winning for one board lot (50 shares), and a subscription of 300,000 shares required to secure one board lot. The international offering recorded 6.3 times subscription. The final offer price was HKD 86.4, at the upper limit of the price range, raising a net amount of HKD 940 million. The shares are expected to be listed on Monday (20th).

Innovative pharmaceutical company HAIXI PHARMA plans to globally offer 11.5 million H shares, with the public offering accounting for 10%. The offer price ranged from HKD 69.88 to HKD 86.4. Cornerstone investor Harvest Oriental SP subscribed for 1.9817 million shares, accounting for 17.23% of the total offering. The final date for the lock-up commitment is April 19, 2026

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.